This analysis used D2d data (individuals with complete screening and baseline visit data) to calculate HGI, identify demographic and clinical variables associated with HGI, and determine how HGI is associated with prediabetes and diabetes diagnosis. These analyses will lay...

A presentation of the results took place at the annual American Diabetes Association meeting in San Francisco on Friday, June 7th. Results were published in the New England Journal of Medicine.  

Traditional recruitment of patients with diabetes or prediabetes has included broad, imprecise methods, such as mass mailings, advertisements, community events, and clinician referrals.  The D2d met its enrollment target in a transformative way by utilizing Electronic Health Records (EHR)...

The last participant study visit was completed at the Northwestern site. This is a very exciting time for both participants and researchers alike! Since the first participant visit in the fall of 2013, more than 29,401 study visits occurred...

Randomized clinical trials that have public health implications but no or low potential for commercial gain are predominantly funded by governmental (e.g., National Institutes of Health (NIH)) and not-for-profit organizations. Judicious management of research studies’ budgets in a milieu...

A future long-term observational follow-up study (with no pills or visits) is being considered for the purpose of collecting simple health information to learn more about vitamin D and health (e.g., diabetes, cancer, heart disease). In anticipation of this...

D2d is the largest clinical trial designed specifically to examine the causal relationship between vitamin D supplementation and the development of diabetes. D2d is also the largest U.S.-based study to have assembled and followed a contemporary cohort of people...

The annual meeting of the D2d research team is held in Washington D.C.. On Sunday evening, Principal Investigator Dr. Pittas presents the State of D2d, which remains very strong, especially following the ‘green light’ by the DSMB following its review...

The Data and Safety Monitoring Board (DSMB) reviews the results of the interim analysis. This is a critical juncture in the conduct of any clinical trial as the DSMB may recommend that the trial be stopped for futility, safety...